

Cancer Biomarker Market: Region, Key Players, Competition and Forecast to 2023

Cancer Biomarker - Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2023

PUNE , INDIA, May 18, 2018 /EINPresswire.com/ -- Introduction

Most healthcare professionals use diagnostic tests to clarify and support their clinical decision making. Cancer biomarkers are substances or processes that indicate the presence of cancers in the human body. Biomarkers may be produced naturally by the affected tissue or by immune cells in the body in response to cancer. Biomarkers are found in the blood, stool, urine, tumor tissue, bodily fluids, or other tissues. Mostly, they improve cancer detection and facilitate high-speed non-invasive diagnosis using genomics and proteomics. The factors incorporate comprehension of disease procedure and shed light about the uniqueness of an individual's tumor at the molecular level. These components are reflected in the changing outline of clinical trials.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/3176676-global-cancer-biomarker-market-research-report-forecast-to-2023>

The increasing preference for targeted therapies for the treatment of patients suffering from different types of malignant cancers is one of the major factors driving the growth of the market.

Pharmaceutical and biotech companies are increasingly focusing on the use of biomarkers in their drug discovery and development process. The strategic alliances for biomarker applications in large-stage clinical trials are fueling the growth of this market.

The global [cancer biomarker](#) market is segmented on the basis of type, application, and end-user.

Based on biomarker type, the market is further segmented into proteomic and genetic biomarkers.

Based on application, the market is segmented into diagnostic, prognostic, and therapeutic. Based on diagnostic the market is further segmented into imaging and no-imaging.

On the basis of end-user, the market is segmented into pharma and biotech companies, diagnostic tool companies, healthcare IT/big data companies, and clinical laboratories.

The global cancer biomarker market was at USD 10,754.0 million in 2016 and is expected to register a CAGR of 15.8 % during the forecast period.

Key Players

F. Hoffmann-La Roche AG (Switzerland), Becton, Dickinson and Company (U.S.), Abbott Laboratories (U.S.), Merck & Co., Inc.(U.S.), GlaxoSmithKline plc (U.K), Novartis AG (Switzerland), PerkinElmer, Inc (U.S.), Bristol-Myers Squibb (U.S.), Bio-Rad Laboratories (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc (U.S.), QIAGEN N.V (Germany), Thermo Fisher Scientific Inc (U.S.), Illumina Inc (U.S.), and others.

Study objectives

To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global cancer biomarker market.

- To provide insights into factors influencing and affecting the market growth
- To provide historical and forecast revenue of market segments and sub-segments with respect to countries

- To provide strategic profiling of key players in the market, and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
- To provide economic factors that influence the global cancer biomarker market
- To provide a detailed analysis of the value chain and supply chain of the global cancer biomarker market

Target Audience

- Pharmaceutical Companies
- Medical Devices Companies
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

Key Findings

- The global cancer biomarker market is expected to reach USD 29,923.5 million by 2023 at a CAGR of 15.8% from 2017 to 2023
- On the basis of type, protein biomarker type commanded the largest market share of 41.8% in 2016
- On the basis of application, the diagnostic segment is expected to command the largest market share of 45.7% over the review period and is also expected to grow at the fastest CAGR of 16.2% during the forecast period, 2017 to 2023
- The Americas holds the largest share of the global cancer biomarker market which is expected to reach USD 11,736.5 million by 2023
- Asia Pacific is the fastest growing market, which is expected to grow at a CAGR of 16.5 % over the forecast period

Table of Content: Key Points

- Chapter 1. Report Prologue
- Chapter 2. Market Introduction
- Chapter 3. Research Methodology
- Chapter 4. Market Dynamics
- Chapter 5. Market Factor Analysis
- Chapter 6 Global Cancer Biomarker Market, By Types
- Chapter 7 Global Cancer Biomarker Market, By Application
- Chapter 8 Global Cancer Biomarker Market, By End Users
- Chapter 9. Global Cancer Biomarker Market, by Region
- ...Continued

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/3176676-global-cancer-biomarker-market-research-report-forecast-to-2023>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2018 IPD Group, Inc. All Right Reserved.